4AZA Bioscience announces research collaboration with Gilead
Companies to Pursue Early-Stage Compounds for the Treatment of Hepatitis C
02-Dec-2005 -
4AZA Bioscience NV announced that the company has entered into a licensing agreement with Gilead Sciences to research and develop compounds for the potential treatment of hepatitis C virus (HCV) infection, a therapeutic area representing a significant unmet medical need. These compounds, ...
GILEAD Sciences
hepatitis C
milestone payments